M. Zarándi

A. Schally, J. Reeves, S. Roberge, 1992, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

Targeted immobilization of neurotransmitters and neuropeptides on agarose and on Acrylex polymers.

B. Penke, J. Varga, M. Zarándi, 1986, Journal of Chromatography A.

Controlled in situ preparation of Aβ(1–42) oligomers from the isopeptide “iso-Aβ(1–42)”, physicochemical and biological characterization

G. Juhász, Á. Kasza, B. Penke, 2010, Peptides.

Synthesis of Aβ[1‐42] and its derivatives with improved efficiency

B. Penke, Z. Bozsó, L. Fülöp, 2007, Journal of peptide science : an official publication of the European Peptide Society.

Inhibition of human androgen-independent PC-3 and DU-145 prostate cancers by antagonists of bombesin and growth hormone releasing hormone is linked to PKC, MAPK and c-jun intracellular signalling.

A. Schally, R. Cai, M. Zarándi, 2005, European journal of cancer.

Mechanisms of ß-Amyloid Neurotoxicity: Perspectives of Pharmacotherapy

T. Harkany, B. Penke, C. Nyakas, 2000, Reviews in the neurosciences.

Preclinical efficacy of growth hormone-releasing hormone antagonists for androgen-dependent and castration-resistant human prostate cancer

A. Schally, K. Burnstein, N. Block, 2014, Proceedings of the National Academy of Sciences.

β‐Amyloid neurotoxicity is mediated by a glutamate‐triggered excitotoxic cascade in rat nucleus basalis

J Korf, T. Harkany, J. Korf, 2000, The European journal of neuroscience.

Antagonists of growth hormone releasing hormone (GHRH) and of bombesin/gastrin releasing peptide (BN/GRP) suppress the expression of VEGF, bFGF, and receptors of the EGF/HER family in PC‐3 and DU‐145 human androgen‐independent prostate cancers

A. Schally, K. Groot, G. Halmos, 2005, The Prostate.

Inhibition of estrogen receptor positive and negative breast cancer cell lines with a growth hormone-releasing hormone antagonist.

A. Schally, O. Ortmann, M. Zarándi, 2008, Oncology reports.

The expression of the pituitary growth hormone-releasing hormone receptor and its splice variants in normal and neoplastic human tissues.

K. Kovitz, A. Schally, K. Groot, 2005, Proceedings of the National Academy of Sciences of the United States of America.

Effective treatment of experimental human non-Hodgkin's lymphomas with antagonists of growth hormone-releasing hormone.

A. Schally, K. Groot, Gabor L. Toller, 2005, Proceedings of the National Academy of Sciences of the United States of America.

Inhibition of growth of human small cell and non-small cell lung carcinomas by antagonists of growth hormone-releasing hormone (GH-RH).

A. Schally, K. Groot, A. Jungwirth, 1996, International journal of oncology.

Inhibition of growth of human osteosarcomas by antagonists of growth hormone-releasing hormone.

A. Schally, K. Groot, K. Szepesházi, 1995, Journal of the National Cancer Institute.

GHRH antagonists reduce the invasive and metastatic potential of human cancer cell lines in vitro.

A. Schally, É. Pozsgai, M. Zarándi, 2010, Cancer letters.

Inhibitory effects of antagonists of growth hormone releasing hormone on experimental prostate cancers are associated with upregulation of wild‐type p53 and decrease in p21 and mutant p53 proteins

A. Schally, G. Halmos, M. Zarándi, 2012, The Prostate.

A Putative Tetrapeptide Antagonist Prevents /3-Amyloid- Induced Long-Term Elevation of [Ca],- in Rat Astrocytes

B. Penke, C. Torday, M. Zarándi, 2019 .

Growth hormone-releasing hormone antagonist induces apoptosis of human endometrial cancer cells through PKCδ-mediated activation of p53/p21.

P. Leung, A. Schally, Jung-Chien Cheng, 2010, Cancer letters.

Suppression of growth of H‐69 small cell lung carcinoma by antagonists of growth hormone releasing hormone and bombesin is associated with an inhibition of protein kinase C signaling

A. Schally, M. Zarándi, J. Varga, 2004, International journal of cancer.

Evaluation of in vitro biological activity of new agmatine analogs of growth hormone-releasing hormone (GH-RH)

A. Schally, M. Zarándi, L. Bokser, 1990 .

Short analogs and mimetics of human urocortin 3 display antidepressant effects in vivo

G. Telegdy, G. Tóth, M. Zarándi, 2014, Peptides.

In vitro model of neurotoxicity of Aβ 1–42 and neuroprotection by a pentapeptide: irreversible events during the first hour

B. Penke, A. Juhász, C. Hetényi, 2004, Neurobiology of Disease.

Amyloid β‐peptide interactions with neuronal and glial cell plasma membrane: binding sites and implications for Alzheimer's disease

B. Penke, M. Zarándi, Y. Verdier, 2004 .

Novel GHRH antagonists suppress the growth of human malignant melanoma by restoring nuclear p27 function

A. Schally, N. Block, A. Krishan, 2014, Cell cycle.

An FT-IR study of the beta-amyloid conformation: standardization of aggregation grade.

B. Penke, É. Klement, K. Soós, 1999, Biochemical and biophysical research communications.

Propionyl-IIGL tetrapeptide antagonizes beta-amyloid excitotoxicity in rat nucleus basalis.

T. Harkany, B. Penke, C. Nyakas, 1999, Neuroreport.

A putative tetrapeptide antagonist prevents beta-amyloid-induced long-term elevation of [Ca2+]i in rat astrocytes.

B. Penke, L. Latzkovits, C. Torday, 1997, Biochemical and biophysical research communications.

Molecular pathomechanisms of Alzheimer's disease

B. Penke, C. Hetényi, K. Soós, 2003 .

Pentapeptide amides interfere with the aggregation of beta-amyloid peptide of Alzheimer's disease.

B. Penke, C. Hetényi, T. Körtvélyesi, 2002, Biochemical and biophysical research communications.

Antiamnesic properties of analogs and mimetics of the tripeptide human urocortin 3

G. Telegdy, M. Zarándi, G. Tóth, 2016, Amino Acids.

Vulnerability of small GABAergic neurons to human beta-amyloid pentapeptide.

B. Penke, M. Pákáski, Péter Kása, 1998, Brain research.

New therapeutic approach to heart failure due to myocardial infarction based on targeting growth hormone-releasing hormone receptor

A. Schally, Lauro M. Takeuchi, J. Hare, 2015, Oncotarget.

Inhibitory effect of antagonists of bombesin and growth hormone-releasing hormone on orthotopic and intraosseous growth and invasiveness of PC-3 human prostate cancer in nude mice.

A. Schally, K. Szepesházi, G. Halmos, 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.

Antagonists of growth hormone releasing hormone (GHRH) given before whole body radiation lead to modulation of radiation response and organ-specific changes in the expression of angiogenesis

A. Markoe, M. Jordá, A. Schally, 2012, Journal of Radiation Oncology.

The Immunohistochemical Expression of Growth Hormone-Releasing Hormone Receptor Splice Variant 1 Is a Favorable Prognostic Marker in Colorectal Cancer

A. Scorilas, C. Petraki, M. Koutsilieris, 2009, Molecular medicine.

Effect of long-acting antagonists of growth hormone (GH)-releasing hormone on GH and cyclic adenosine 3',5'-monophosphate release in superfused rat pituitary cells.

A. Schally, K. Groot, J. Horváth, 1995, Endocrinology.

Synthesis of two peptide scorpion toxins and their use to investigate the aortic tissue regulation

J. Papp, B. Penke, T. Janáky, 1995, Peptides.

Cytotoxic analogs of luteinizing hormone-releasing hormone containing doxorubicin or 2-pyrrolinodoxorubicin, a derivative 500-1000 times more potent.

M Kovacs, A. Schally, K. Groot, 1996, Proceedings of the National Academy of Sciences of the United States of America.

Development of a polyclonal antiserum for the detection of the isoforms of the receptors for human growth hormone-releasing hormone on tumors.

A. Schally, K. Groot, Gabor L. Toller, 2004, Proceedings of the National Academy of Sciences of the United States of America.

Modulation of the effects of morphine by cholecystokinin in rats

B. Penke, G. Telegdy, M. Zarándi, 1989 .

Beneficial effects of novel antagonists of GHRH in different models of Alzheimer's disease

A. Schally, N. Block, R. Cai, 2012, Aging.

Synthesis and in vitro and in vivo activity of analogs of growth hormone-releasing hormone (GH-RH) with C-terminal agmatine.

A. Schally, K. Groot, V. Csernus, 2009, International journal of peptide and protein research.

β-Amyloid-Induced Cholinergic Denervation Correlates with Enhanced Nitric Oxide Synthase Activity in Rat Cerebral Cortex: Reversal by NMDA Receptor Blockade

T. Harkany, B. Leonard, B. Penke, 1998, Brain Research Bulletin.

β-Amyloid(1-42)-Induced Cholinergic Lesions in Rat Nucleus Basalis Bidirectionally Modulate Serotonergic Innervation of the Basal Forebrain and Cerebral Cortex

T. Harkany, J. Kelly, B. Leonard, 2001, Neurobiology of Disease.

University of Groningen β-Amyloid ( 1-42 )-Induced Cholinergic Lesions in Rat Nucleus Basalis Bidirectionally Modulate Serotonergic Innervation of the Basal Forebrain and Cerebral Cortex

T. Harkany, J. Kelly, B. Leonard, 2018 .

Beta-amyloid(1-42)-induced cholinergic lesions in rat nucleus basalis bidirectionally modulate serotonergic innervation of the basal forebrain and cerebral cortex.

T. Harkany, J. Kelly, B. Leonard, 2001, Neurobiology of disease.

Suppression of the proliferation of human U-87 MG glioblastoma cells by new antagonists of growth hormone-releasing hormone in vivo and in vitro

A. Schally, A. Jayakumar, N. Block, 2013, Targeted Oncology.

Endothelium‐dependent Vasorelaxant and Anti‐aggregatory Effect and Mechanism of Action of Some Antifibrinogen RGD (Arg‐Gly‐Asp‐containing) Peptides

J. Papp, B. Penke, L. L. Torday, 1998, The Journal of pharmacy and pharmacology.

Endocrine and antineoplastic actions of growth hormone-releasing hormone antagonists.

A. Schally, M. Zarándi, M. Kovács, 2008, Current medicinal chemistry.

Lipopeptide antagonists of growth hormone-releasing hormone with improved antitumor activities.

A. Schally, K. Groot, Gabor L. Toller, 2006, Proceedings of the National Academy of Sciences of the United States of America.

Dose‐dependent growth inhibition in vivo of PC‐3 prostate cancer with a reduction in tumoral growth factors after therapy with GHRH antagonist MZ‐J‐7‐138

A. Schally, K. Groot, G. Halmos, 2008, The Prostate.

Antagonists of growth hormone releasing hormone (GHRH) and of bombesin/gastrin releasing peptide (BN/GRP) suppress the expression of VEGF, bFGF, and receptors of the EGF/HER family in PC-3 and DU-145 human androgen-independent prostate cancers

A. Schally, K. Groot, G. Halmos, 2005 .

Growth Hormone-Releasing Hormone Antagonists Inhibit Growth of Human Ovarian Cancer

A. Schally, A. Papadia, J. Lucci, 2011, Hormone and Metabolic Research.

The combination of antagonists of LHRH with antagonists of GHRH improves inhibition of androgen sensitive MDA‐PCa‐2b and LuCaP‐35 prostate cancers

A. Schally, K. Groot, A. Havt, 2007, The Prostate.

Antagonists of growth hormone releasing hormone and bombesin inhibit the expression of EGF/HER receptor family in H-69 small cell lung carcinoma.

A. Schally, G. Halmos, M. Zarándi, 2005, Cancer letters.

Pentapeptides derived from A beta 1-42 protect modulatory effect of A beta fibrils - an in vivo electrophysiological study

D. Budai, J. Toldi, B. Penke, 2005 .

Antagonists of growth hormone-releasing hormone (GHRH) reduce prostate size in experimental benign prostatic hyperplasia

M. Nadji, A. Schally, K. Szepesházi, 2011, Proceedings of the National Academy of Sciences.

Differences between normal and alpha-synuclein overexpressing SH-SY5Y neuroblastoma cells after Aβ(1-42) and NAC treatment

Á. Hunya, B. Penke, István Földi, 2008, Brain Research Bulletin.